nCAP Medical Announces Publication of Positive RCT Results Demonstrating NeuroCuple® Provides Meaningful, Opioid-Sparing Pain Relief Immediately Following Total Knee Arthroplasty
The study, published in the Journal of Arthroplasty, highlighted that the Company’s NeuroCuple® Nanotechnology Device achieved statistically significant reduction in opioid use, pain, and hospital length of stay, as well as clinically significant reductions in postoperative nausea and vomiting (PONV), and rescue antiemetic use following total knee arthroplasty (TKA) HEBER CITY, Utah, June 16, 2026 -- nCAP Medical, Inc. (“nCAP Medical”, or the “Company”), a medical technology company developing NeuroCuple®, a non-opioid platform for chronic and acute pain, today announced the results as published in The Journal of Arthroplasty, demonstrated its NeuroCuple® Nanotechnology Device achieves clinically, statistically, and economically significant reductions in…

